Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled trial.
Junko TakahashiSatoko KandaIchiro ImanishiTadashi HisanoTeruyasu FukamachiNorihito TaguchiShoko MomiyamaSatoshi NishiyamaTomoki MotegiKeita IyoriPublished in: Veterinary dermatology (2020)
Topical application of 0.0584% HCA spray may be useful for preventing exacerbation of pruritus and clinical lesions when tapering oclacitinib therapy in dogs with AD.